Bristol Myers Squibb (BMS) has disclosed positive data from two pivotal trials for its drug, Sotkytu, in treating psoriatic arthritis. The results could help expand the use of the drug, which is a TYK2 inhibitor, beyond its current approval for treating plaque psoriasis. This could boost the product’s revenue and offer patients an alternative treatment option. The company plans to share detailed results at future medical conferences.
Clop Ransomware is Now Blackmailing 66 Cleo Data-Theft Victims, Reports DataBreaches.Net
Right, let’s sit down for a chat about the state of play in cybersecurity. You know that old saying about ‘an Englishman’s home is his
